Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Hepatitis B virus (HBV)-DNA integration in HBV-related hepatocellular carcinoma (HBV-HCC) can be targeted by HBV-specific T cells. SCG101 is an autologous, HBV-specific T-cell product expressing a T-cell receptor (TCR) after lentiviral transduction recognizing the envelope-derived peptide (S20-28) on HLA-A2. We here validated its safety and efficacy preclinically and applied it to an HBV-related HCC patient (NCT05339321). Methods: Good Manufacturing Practice-grade manufactured cells were assessed for off-target reactivity and functionality against hepatoma cells. Subsequently, a patient with advanced HBV-HCC (Child-Pugh class A, Barcelona Clinic Liver Cancer stage B, Eastern Cooperative Oncology Group performance status 0, hepatitis B e antigen-, serum hepatitis B surface antigen [HBsAg]+, HBsAg+ hepatocytes 10%) received 7.9×107 cells/kg after lymphodepletion. Safety, T-cell persistence, and antiviral and antitumor efficacy were evaluated. Results: SCG101, produced at high numbers in a closed-bag system, showed HBV-specific functionality against HBV-HCC cells in vitro and in vivo. Clinically, treatment was well tolerated, and all adverse events, including transient hepatic damage, were reversible. On day 3, ALT levels increased to 1,404 U/L, and concurrently, serum HBsAg started decreasing by 3.84 log10 and remained <1 IU/mL for over six months. HBsAg-expressing hepatocytes in liver biopsies were undetectable after 73 days. The patient achieved a partial response according to modified RECIST with a >70% reduction in target lesion size. Transferred T cells expanded, developed a stem cell-like memory phenotype, and were still detectable after six months in the patient’s blood. Conclusions: SCG101 T-cell therapy showed encouraging efficacy and safety in preclinical models and in a patient with primary HBV-HCC and concomitant chronic hepatitis B with the capability to eliminate HBsAg+ cells and achieve sustained tumor control after single dosing.
Abstract
Background/Aims: Hepatitis B virus (HBV)-DNA integration in HBV-related hepatocellular carcinoma (HBV-HCC) can be targeted by HBV-specific T cells. SCG101 is an autologous, HBV-specific T-cell product expressing a T-cell receptor (TCR) after lentiviral transduction recognizing the envelope-derived peptide (S20-28) on HLA-A2. We here validated its safety and efficacy preclinically and applied it to an HBV-related HCC patient (NCT05339321). Methods: Good Manufacturing Practice-grade manufactured cells were assessed for off-target reactivity and functionality against hepatoma cells. Subsequently, a patient with advanced HBV-HCC (Child-Pugh class A, Barcelona Clinic Liver Cancer stage B, Eastern Cooperative Oncology Group performance status 0, hepatitis B e antigen-, serum hepatitis B surface antigen [HBsAg]+, HBsAg+ hepatocytes 10%) received 7.9×107 cells/kg after lymphodepletion. Safety, T-cell persistence, and antiviral and antitumor efficacy were evaluated. Results: SCG101, produced at high numbers in a closed-bag system, showed HBV-specific functionality against HBV-HCC cells in vitro and in vivo. Clinically, treatment was well tolerated, and all adverse events, including transient hepatic damage, were reversible. On day 3, ALT levels increased to 1,404 U/L, and concurrently, serum HBsAg started decreasing by 3.84 log10 and remained <1 IU/mL for over six months. HBsAg-expressing hepatocytes in liver biopsies were undetectable after 73 days. The patient achieved a partial response according to modified RECIST with a >70% reduction in target lesion size. Transferred T cells expanded, developed a stem cell-like memory phenotype, and were still detectable after six months in the patient’s blood. Conclusions: SCG101 T-cell therapy showed encouraging efficacy and safety in preclinical models and in a patient with primary HBV-HCC and concomitant chronic hepatitis B with the capability to eliminate HBsAg+ cells and achieve sustained tumor control after single dosing.
참고문헌 (61)
- Sung H, "et al Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries", CA Cancer J Clin, 71, pp.209~249 (2021)
- Zhang H, "Recent advances in systemic therapy for hepatocellular carcinoma", Biomark Res, 10, pp.3~ (2022)
- Zheng R, "Liver cancer incidence and mortality in China : Temporal trends and projections to 2030", Chin J Cancer Res, 30, pp.571~579 (2018)
- Sung WK, "Genomewide survey of recurrent HBV integration in hepatocellular carcinoma", Nat Genet, 44, pp.765~769 (2012)
- Tu T, "Clonal expansion of hepatocytes with a selective advantage occurs during all stages of chronic hepatitis B virus infection", J Viral Hepat, 22, pp.737~753 (2015)
- Mason WS, "Hepatitis B virus DNA integration and clonal expansion of hepatocytes in the chronically infected liver", Viruses, 13, pp.210~ (2021)
- Ringlander J, "Deep sequencing of liver explant transcriptomes reveals extensive expression from integrated hepatitis B virus DNA", J Viral Hepat, 27, pp.1162~1176 (2020)
- Su IJ, "Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection", J Gastroenterol Hepatol, 23, pp.1169~1174 (2008)
- Zheng Y, "In situ analysis of hepatitis B virus(HBV)antigen and DNA in HBVinduced hepatocellular carcinoma", Diagn Pathol, 17, pp.11~ (2022)
- Wang Y, "Different expression of hepatitis B surface antigen between hepatocellular carcinoma and its surrounding liver tissue, studied using a tissue microarray", J Pathol, 197, pp.610~616 (2002)
- Tantiwetrueangdet A, "Reduced HBV cccDNA and HBsAg in HBV-associated hepatocellular carcinoma tissues", Med Oncol, 35, pp.127~ (2018)
- Fu S, "Detection of HBV DNA and antigens in HBsAg-positive patients with primary hepatocellular carcinoma", Clin Res Hepatol Gastroenterol, 41, pp.415~423 (2017)
- Tan AT, "Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy", Gastroenterology, 156, pp.1862~1876 (2019)
- Srivastava M, "Proteogenomic identification of Hepatitis B virus(HBV)genotype-specific HLA-I restricted peptides from HBV-positive patient liver tissues", Front Immunol, 13, pp.1032716~ (2022)
- de Beijer MTA, "Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma", JHEP Rep, 4, pp.100576~ (2022)
- Gehring AJ, "Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines", J Hepatol, 55, pp.103~110 (2011)
- Wisskirchen K, "Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use", PLoS One, 12, pp.e0182936~ (2017)
- Wisskirchen K, "T cell receptor grafting allows virological control of Hepatitis B virus infection", J Clin Invest, 129, pp.2932~2945 (2019)
- Sommermeyer D, "Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells", J Immunol, 184, pp.6223~6231 (2010)
- Porter DL, "Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia", Sci Transl Med, 7, pp.303ra139~ (2015)
- Louis CU, "Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma", Blood, 118, pp.6050~6056 (2011)
- Festag J, "Vector-mediated delivery of human major histocompatibility complex-I into hepatocytes enables investigation of T cell receptor-redirected hepatitis B virus-specific T cells in mice, and in macaque cell cultures", Hum Gene Ther, 34, pp.1204~1218 (2023)
- Lee DW, "ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells", Biol Blood Marrow Transplant, 25, pp.625~638 (2019)
- Shimabukuro-Vornhagen A, "Cytokine release syndrome", J Immunother Cancer, 6, pp.56~ (2018)
- Turtle CJ, "CD19 CAR-T cells of defined CD4+ : CD8+ composition in adult B cell ALL patients", J Clin Invest, 126, pp.2123~2138 (2016)
- Muranski P, "Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?", Nat Clin Pract Oncol, 3, pp.668~681 (2006)
- Kielsen K, "IL-7 and IL-15 levels reflect the degree of T cell depletion during lymphopenia and are associated with an expansion of effector memory T cells after pediatric hematopoietic stem cell transplantation", J Immunol, 206, pp.2828~2838 (2021)
- Heczey A, "CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma", Mol Ther, 25, pp.2214~2224 (2017)
- Festag MM, "Evaluation of a fully human, hepatitis B virus-specific chimeric antigen receptor in an immunocompetent mouse model", Mol Ther, 27, pp.947~959 (2019)
- European Association for the Study of the Liver, "EASL 2017Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Shouval D, "Adoptive transfer of immunity to HBV in liver transplant patients : a step forward toward the proof of concept for therapeutic vaccination or a transient immunologic phenomenon?", Liver Transpl, 13, pp.14~17 (2007)
- Sonneveld MJ, "Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response", Clin Infect Dis, 56, pp.100~105 (2013)
- Chi H, "Flares during long-term entecavir therapy in chronic hepatitis B", J Gastroenterol Hepatol, 31, pp.1882~1887 (2016)
- Montanari NR, "Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection", J Hepatol, 77, pp.332~343 (2022)
- Meier MA, "Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load", J Hepatol, 75, pp.840~847 (2021)
- Aggarwal A, "Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatmentmediated reductions in HBV core-positive cells", JHEP Rep, 5, pp.100664~ (2022)
- Cheng PN, "HBsAg expression of liver correlates with histological activities and viral replication in chronic hepatitis B", Ann Hepatol, 13, pp.771~780 (2014)
- Chu CM, "Membrane staining for hepatitis B surface antigen on hepatocytes : a sensitive and specific marker of active viral replication in hepatitis B", J Clin Pathol, 48, pp.470~473 (1995)
- Wursthorn K, "Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B", Hepatology, 44, pp.675~684 (2006)
- Thompson AJ, "Serum hepatitis B surface antigen and hepatitis B e antigen titers : disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers", Hepatology, 51, pp.1933~1944 (2010)
- Chen W, "Noninvasive chimeric DNA profiling identifies tumor-originated HBV integrants contributing to viral antigen expression in liver cancer", Hepatol Int, 14, pp.326~337 (2020)
- Svicher V, "Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B", Gut, 70, pp.2337~2348 (2021)
- Rydell GE, "Abundance of noncircular intrahepatic hepatitis B virus DNA may reflect frequent integration into human DNA in chronically infected patients", J Infect Dis, 225, pp.1982~1990 (2022)
- Grudda T, "Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment", J Clin Invest, 132, pp.e161818~ (2022)
- Revill P, "Global strategies are required to cure and eliminate HBV infection", Nat Rev Gastroenterol Hepatol, 13, pp.239~248 (2016)
- Yuen MF, "RNA interference therapy with ARC-520 results in prolonged hepatitis B surface antigen response in patients with chronic hepatitis B infection", Hepatology, 72, pp.19~31 (2020)
- Wooddell CI, "RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg", Sci Transl Med, 9, pp.eaan0241~ (2017)
- Wooddell CI, "RNA interference therapy for chronic hepatitis B predicts the importance of addressing viral integration when developing novel cure strategies", Viruses, 13, pp.581~ (2021)
- Cornberg M, "Hepatitis : No cure for hepatitis B and D without targeting integrated viral DNA?", Nat Rev Gastroenterol Hepatol, 15, pp.195~196 (2018)
- Nagarsheth NB, "TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers", Nat Med, 27, pp.419~425 (2021)
- Baudi I, "HBV-specific CD8+ T-cell tolerance in the liver", Front Immunol, 12, pp.721975~ (2021)
- You M, "Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBVrelated HCC", Hepatology, 78, pp.943~958 (2023)
- Meng F, "Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells : results of dose escalation, phase I trial", Hepatol Int, 15, pp.1402~1412 (2021)
- Tan AT, "Immunological alterations after immunotherapy with short lived HBVTCR T cells associates with long-term treatment response in HBV-HCC", Hepatol Commun, 6, pp.841~854 (2022)
- Silver HK, "The detection of alpha 1-fetoprotein in patients with viral hepatitis", Cancer Res, 34, pp.244~247 (1974)
- Hanif H, "Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma", World J Gastroenterol, 28, pp.216~229 (2022)
- Qasim W, "Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient", J Hepatol, 62, pp.486~491 (2015)
- Sommermeyer D, "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo", Leukemia, 30, pp.492~500 (2016)
- Li Y, "Immunotherapeutic potential of T memory stem cells", Front Oncol, 11, pp.723888~ (2021)
- Biasco L, "Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients", Nat Cancer, 2, pp.629~642 (2021)
- Reinhard K, "An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors", Science, 367, pp.446~453 (2020)